Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

Summary Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII, porcine sequence, with low cross‐reactivity to anti‐hFVIII antibodies. Efficacy can be monitored with FVIII...

Full description

Saved in:

Bibliographic Details
Published in:	Haemophilia : the official journal of the World Federation of Hemophilia Vol. 21; no. 2; pp. 162 - 170
Main Authors:	Kruse-Jarres, R., St-Louis, J., Greist, A., Shapiro, A., Smith, H., Chowdary, P., Drebes, A., Gomperts, E., Bourgeois, C., Mo, M., Novack, A., Farin, H., Ewenstein, B.
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01.03.2015 Wiley Subscription Services, Inc
Subjects:	acquired haemophilia A Adult Aged Aged, 80 and over Animals Antibodies, Neutralizing Autoantibodies Autoantibodies - immunology Bleeding bleeding episodes Coagulation factors Cross Reactions - immunology Dosage Factor VIII - administration & dosage Factor VIII - adverse effects Factor VIII - immunology Factor VIII - therapeutic use Female Hemophilia Hemophilia A - drug therapy Hemophilia A - immunology Humans Hypersensitivity Male Middle Aged recombinant FVIII porcine sequence Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Recombinant Proteins - immunology Recombinant Proteins - therapeutic use replacement therapy Swine Thrombocytopenia Time Factors Treatment Outcome acquired haemophilia A bleeding episodes recombinant FVIII porcine sequence replacement therapy
ISSN:	1351-8216, 1365-2516, 1365-2516
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!